Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADRRAD trial in newly presenting metastatic castration-sensitive prostate cancer
2014-000273-39Phase 2Unknown
- Sponsor
- Belfast Health and Social Care Trust
- Start
- Jul 2015
- Modality
- Small Molecules, Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of radium-223 dichloride, goserelin, leuprolide and triptorelin in prostate cancer (PCa) and prostate adenocarcinoma, sponsored by Belfast Health and Social Care Trust. Primary endpoint: Toxicity of concurrent combined treatment. Status: unknown.
02
Drugs
radium-223 dichloridegoserelinleuprolidetriptorelin
03
Conditions
prostate cancer (PCa)prostate adenocarcinoma
Beyond the preview
Go deeper on 2014-000273-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000273-39.